Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Rheumatology International
Published in: Rheumatology International 7/2006

01-05-2006 | Review

Current concepts in the pathophysiology of fibromyalgia: the potential role of oxidative stress and nitric oxide

Authors: Salih Ozgocmen, Huseyin Ozyurt, Sadik Sogut, Omer Akyol

Published in: Rheumatology International | Issue 7/2006

Login to get access

Abstract

Fibromyalgia (FM) is a common chronic pain syndrome with an unknown etiology. Recent years added new information to our understanding of FM pathophysiology. Researches on genetics, biogenic amines, neurotransmitters, hypothalamic-pituitary-adrenal axis hormones, oxidative stress, and mechanisms of pain modulation, central sensitization, and autonomic functions in FM revealed various abnormalities indicating that multiple factors and mechanisms are involved in the pathogenesis of FM. Oxidative stress and nitric oxide may play an important role in FM pathophysiology, however it is still not clear whether oxidative stress abnormalities documented in FM are the cause or the effect. This should encourage further researches evaluating the potential role of oxidative stress and nitric oxide in the pathophysiology of FM and the efficacy of antioxidant treatments (omega-3 and -6 fatty acids, vitamins and others) in double blind and placebo controlled trials. These future researches will enhance our understanding of the complex pathophysiology of this disorder.
Literature
1.
Neeck G (2002) Pathogenic mechanisms of fibromyalgia. Aging Res Rev 1:243–255CrossRef
2.
Mease P (2005) Fibromyalgia syndrome: review of clinical presentation, pathogenesis, outcome measures and treatment. J Rheumatol 32(Suppl 75):6–21PubMed
3.
Ozgocmen S (2005) New strategies in evaluation of therapeutic efficacy in fibromyalgia syndrome. Curr Pharm Des (in press)
4.
Buskila D, Neumann L, Hazanov I, Carmi R (1996) Familial aggregation in the fibromyalgia syndrome. Semin Arthritis Rheum 26:605–611CrossRefPubMed
5.
Offenbaecher M, Bondy B, de Jonge S et al (1999) Possible association of fibromyalgia with a polymorphism in the serotonin transporter gene regulatory region. Arthritis Rheum 42:2482–2488CrossRefPubMed
6.
Yunus MB, Khan MA, Rawlings KK et al (1999) Genetic linkage analysis of multicase families with fibromyalgia syndrome. J Rheumatol 26:408–412PubMed
7.
Buskila D, Neumann L (1997) Fibromyalgia syndrome (FM) and nonarticular tenderness in relatives of patients with FM. J Rheumatol 24:941–944PubMed
8.
Arnold LM, Hudson JI, Hess EV et al (2004) Family study of fibromyalgia. Arthritis Rheum 50:944–952CrossRefPubMed
9.
Cohen H, Buskila D, Neumann L, Ebstein RP (2002) Confirmation of an association between fibromyalgia and serotonin transporter promoter region (5-HTTLPR) polymorphism, and relationship to anxiety-related personality traits. Arthritis Rheum 46:845–847CrossRefPubMed
10.
Gursoy S, Erdal E, Herken H, Madenci E, Alasehirli B, Erdal N (2003) Significance of catechol-O-methyltransferase gene polymorphism in fibromyalgia syndrome. Rheumatol Int 23:104–107
11.
Buskila D, Cohen H, Neumann L, Ebstein RP (2004) An association between fibromyalgia and the dopamine D4 receptor exon III repeat polymorphism and relationship to novelty seeking personality traits. Mol Psychiatry 9:730–731PubMed
12.
Klein R, Beansch M, Berg PA (1992) Clinical relevance of antibodies against serotonin and gangliosides in patients with primary fibromyalgia syndrome. Psychoneuroendocrinology 17:593–598CrossRefPubMed
13.
Werle E, Fisher H, Muller A et al (2001) Antibodies against serotonin have no diagnostic relevance in patients with fibromyalgia syndrome. J Rheumatol 28:595–600PubMed
14.
Greenfield S, Fitzcharles MA, Esdaile JM (1992) Reactive fibromyalgia syndrome. Arthritis Rheum 35:678–681PubMed
15.
Buskila D, Neumann L, Vaisberg G, Alkalay D, Wolfe F (1997) Increased rates of fibromyalgia following cervical spine injury. A controlled study of 161 cases of traumatic injury. Arthritis Rheum 40:446–452PubMed
16.
Boisset-Pioro MH, Esdaile JM, Fitzcharles M (1995) Sexual and physical abuse in women with fibromyalgia syndrome. Arthritis Rheum 38:235–241PubMed
17.
Ciccone DS, Elliott DK, Chandler HK, Nayak S, Raphael KG (2005) Sexual and physical abuse in women with fibromyalgia syndrome. A test of the trauma hypothesis. Clin J Pain 21:378–386CrossRefPubMed
18.
Buskila D, Shnaider A, Neumann L, Zilberman D, Hilzenrat N, Sikuler E (1997) Fibromyalgia in hepatitis C virus infection. Another infectious disease relationship. Arch Intern Med 157:1497–1500CrossRef
19.
Staud R (2002) Evidence of involvement of central neural mechanisms in generating fibromyalgia pain. Curr Rheumatol Rep 4:299–305PubMed
20.
van Denderen JC, Boersma JW, Zeinstra P et al (1992) Physiological effects of exhaustive physical exercise in primary fibromyalgia syndrome (PFS): is PFS a disorder of neuroendocrine reactivity? Scand J Rheumatol 21:35–37PubMed
21.
Alnigenis MNY, Barland P (2001) Fibromyalgia syndrome and serotonin. Clin Exp Rheumatol 19:205–210PubMed
22.
Moldofsky H (1982) Rheumatic pain modulation syndromes: the interrelationships between sleep, central nervous system, serotonin and pain. Adv Neurol 33:51–57PubMed
23.
Russell IJ, Bowden CL, Michalek J et al (1987) Imipramine receptor density on platelets of patients with fibrositis syndrome: correlation with disease severity and response to therapy. Arthritis Rheum 30:63
24.
Russell IJ, Michalek JE, Vipraio GA, Fletcher EM, Javors MA, Bowden CA (1992) Platelet 3H-imipramine uptake receptor density and serum serotonin levels in patients with fibromyalgia/fibrositis syndrome. J Rheumatol 19:104–109PubMed
25.
Russell IJ, Michalek JE, Vipraio GA, Fletcher EM, Wall K (1989) Serum amino acids in fibrositis/fibromyalgia syndrome. J Rheumatol 19:158–163
26.
Yunus MB, Dailey JW, Aldag JC, Masi AT, Jobe PC (1992) Plasma tryptophan and other amino acids in primary fibromyalgia:A controlled study. J Rheumatol 19:90–94PubMed
27.
Russell IJ,Vaeroy H, Javors M, Nyberg F (1992) Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum 35:550–556PubMed
28.
Houvenagel E, Forzy G, Cortet B, Vincent G (1990) 5-hydroxy indol acetic acid in cerebrospinal fluid in fibromyalgia. Arthritis Rheum 33(Suppl 9):S55
29.
Mense S (2000) Neurobiological concepts of fibromyalgia-the possible role of descending spinal tracts. Scand J Rheumatol 29(suppl 113):24–29CrossRef
30.
Larson AA, Giovengo SL, Russell IJ, Michalek JE (2000) Changes in the concentrations of amino acids in the cerebrospinal fluid that correlate with pain in patients with fibromyalgia: implications for nitric oxide pathways. Pain 87:201–211CrossRefPubMed
31.
Vaeroy H, Helle R, Forre O (1988) Elevated CSF levels of substance P and high incidence of Raynaud phenomenon in patients with fibromyalgia: new features for diagnosis. Pain 32:21–26CrossRefPubMed
32.
Russell IJ, Littman B (1994) Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum 37:1593–1601PubMed
33.
Schwarz MJ, Spath M, Muller-Bardorff H, Pongratz DE, Bondy B, Ackenheil M (1999) Relationship of substance P, 5-hydroxyindole acetic acid and tryptophan in serum of fibromyalgia patients. Neurosci Lett 259:196–198CrossRefPubMed
34.
Croffors LJ (2002) The hypothalamic-pituitary-adrenal axis in fibromyalgia: Where are we in 2001. J Musculuskelet Pain 10:215–220CrossRef
35.
Griep EN, Boersma JW, de Kloet ER (1993) Altered reactivity of the hypothalamic-pituitary-adrenal axis in the primary fibromyalgia syndrome. J Rheumatol 20:469–474PubMed
36.
Riedel W, Layka H, Neeck G (1998) Secretory pattern of GH, TSH, thyroid hormones, ACTH, cortisol, FSH, and LH in patients with fibromyalgia syndrome following systemic injection of the relevant hypothalamic-releasing hormones. Z Rheumatol 57(Suppl 2):81–87CrossRefPubMed
37.
Adler GK, Kinsley BT, Hurwitz S, Mossey CJ, Goldenberg DL (1999) Reduced hypothalamic-pituitary and sympathoadrenal responses to hypoglycemia in women with fibromyalgia syndrome. Am J Med 106:534–543CrossRefPubMed
38.
Kirnap M, Colak R, Eser C, Ozsoy O, Tutus A, Kelestimur F (2001) A comparison between low-dose (1 microg), standard-dose (250 microg) ACTH stimulation tests and insulin tolerance test in the evaluation of hypothalamo-pituitary-adrenal axis in primary fibromyalgia syndrome. Clin Endocrinol 55:455–459CrossRef
39.
Torpy DJ, Papanicolaou DA, Lotsikas AJ, Wilder RL, Chrousos GP, Pillemer SR (2000) Responses of the sympathetic nervous system and the hypothalamic-pituitary-adrenal axis to interleukin-6: a pilot study in fibromyalgia. Arthritis Rheum 43:872–880CrossRefPubMed
40.
Gur A, Cevik R, Nas K, Colpan L, Sarac S (2004) Cortisol and hypothalamic-pituitary-gonadal axis hormones in follicular-phase women with fibromyalgia and chronic fatigue syndrome and effect of depressive symptoms on these hormones. Arthritis Res Ther 6:R232-R238CrossRefPubMed
41.
Gur A, Cevik R, Sarac AJ, Colpan L, Em S (2004) Hypothalamic-pituitary-gonadal axis and cortisol in young women with primary fibromyalgia: the potential roles of depression, fatigue, and sleep disturbance in the occurrence of hypocortisolism. Ann Rheum Dis 63:1504–1506CrossRefPubMed
42.
Martinez-Lavin M (2002) Management of dysautonomia in fibromyalgia. Rheum Dis Clin North Am 28:379–387CrossRefPubMed
43.
Martinez-Lavin M, Hermosillo AG (2000) Autonomic nervous system dysfunction may explain the multisystem features of fibromyalgia. Semin Arthritis Rheum 29:197–199CrossRefPubMed
44.
Bengtsson A, Bengtsson M (1988) Regional sympathetic blockade in primary fibromyalgia. Pain 33:161–167CrossRefPubMed
45.
Elam M, Johansson G, Wallin BG (1992) Do patients with primary fibromyalgia have an altered muscle sympathetic nerve activity? Pain 48:371–375CrossRefPubMed
46.
Wachter KC, Kaeser HE, Guhring H et al (1996) Muscle damping measured with a modified pendulum test in patients with fibromyalgia, lumbago, and cervical syndrome. Spine 21:2137–2142CrossRefPubMed
47.
Martinez-Lavin M, Hermosillo AG, Mendoza C et al (1997) Orthostatic sympathetic derangement in subject with fibromyalgia. J Rheumatol 24:714–718PubMed
48.
Kelemen J, Lang E, Balint G, Trocsanyi M, Muller W (1998) Orthostatic sympathetic derangement of baroreflex in patients with fibromyalgia. J Rheumatol 25:823–825PubMed
49.
Raj RR, Brouillard D, Simpson CS, Hopman WM, Abdollah H (2000) Dysautonomia among patients with fibromyalgia: A noninvasive assessment. J Rheumatol 27:2660–2665PubMed
50.
Martinez-Lavin M, Hermosillo AG, Rosas M, Soto ME (1998) Circadian studies of autonomic nervous balance in patients with fibromyalgia. A heart rate variability analysis. Arthritis Rheum 42:1966–1971CrossRef
51.
Wallace DJ (2005) Is there a role for cytokine based therapies in fibromyalgia. Curr Pharm Des (in press)
52.
Lloyd A, Gandevia S, Brockman A, Hales J, Wakefield D (1994) Cytokine production and fatigue in patients with chronic fatigue syndrome and healthy control subjects in response to exercise. Clin Infect Dis 1:142–146
53.
Wallace DJ, Linker-Israeli M, Hallegua D, Silverman S, Silver D, Weisman MH (2001) Cytokines play an aetiopathogenetic role in fibromyalgia: a hypothesis and pilot study. Rheumatology 40:743–749CrossRefPubMed
54.
Amel Kashipaz MR, Swinden KD, Todd I, Powell RJ (2003) Normal production of inflammatory cytokines in chronic fatigue and fibromyalgia syndromes determined by intracellular cytokine staining in short-term cultured blood mononuclear cells. Clin Exp Immunol 132:360–365CrossRefPubMed
55.
Gur A, Karakoc M, Nas K, Cevik R, Denli A, Sarac J (2002) Cytokines and depression in cases with fibromyalgia. J Rheumatol 29:358–361PubMed
56.
Gur A, Karakoc M, Erdogan S, Nas K, Cevik R, Sarac AJ (2002) Regional cerebral blood flow and cytokines in young females with fibromyalgia. Clin Exp Rheumatol 20:753–760PubMed
57.
Salemi S, Rethage J, Wollina U, Michel BA, Gay RE, Gay S, Sprott H (2003) Detection of interleukin 1beta (IL-1beta), IL-6, and tumor necrosis factor-alpha in skin of patients with fibromyalgia. J Rheumatol 30:146–150PubMed
58.
Sperber AD, Weisberg I, Skibin A, Neumann L, Fich A, Buskila D (1999) Serum interleukin-1, interleukin-Interleukin-6 and prolactin levels are not associated with severity of disease in patients with the irritable bowel syndrome, with or without concomitant fibromyalgia. J Musculoskelet Pain 7:5–27CrossRef
59.
Jones AKP, Kulkarni B, Derbyshire SWG (2002) Functional imaging of pain perception. Curr Rheumatol Rep 4:329–333PubMed
60.
Bradley LA, McKendree-Smith NL, Alberts KR, Alarcon GS, Mountz JM, Deutsch G (2000) Use of neuroimaging to understand abnormal pain sensitivity in fibromyalgia. Curr Rheumatol Rep 2:141–148PubMed
61.
Gur A, Karakoc M, Erdogan S, Nas K, Cevik R, Sarac AJ (2002) Regional cerebral blood flow and cytokines in young females with fibromyalgia. Clin Exp Rheumatol 20:753–760PubMed
62.
Gracely RH, Petzke F, Wolf JM, Clauw DJ (2002) Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia. Arthritis Rheum 46:1333–1343CrossRefPubMed
63.
Mountz JM, Bradley LA, Modell JG, Alexander RW, Triana-Alexander M, Aaron LA et al (1995) Fibromyalgia in women: abnormalities of regional cerebral blood flow in the thalamus and the caudate nucleus are associated with low pain threshold levels. Arthritis Rheum 38:926–938PubMed
64.
Kwiatek R, Barnden L, Tedman R, Jarrett R, Chew J, Rowe C et al (2000) Regional cerebral blood flow in fibromyalgia: singlephoton—emission computed tomography evidence of reduction in the pontine tegmentum and thalami. Arthritis Rheum 43:2823–2833CrossRefPubMed
65.
Ozgocmen S, Yoldas T, Kamanli A, Yildizhan H, Yigiter R, Ardicoglu O (2003) Auditory P300 event related potentials and serotonin reuptake inhibitor treatment in patients with fibromyalgia. Ann Rheum Dis 62:551–555CrossRefPubMed
66.
Alberts KR, Bradley LA, Alarcon GS, Mountz JM, Ford CV, Deutsch G et al (1998) Sertraline hydrochloride alters pain threshold, sensory discrimination ability, and functional brain activity in patients with fibromyalgia (FM): a randomized, controlled trial. Arthritis Rheum 41(Suppl S):1358
67.
Staud R (2005) Are tender point injections beneficial: The role of tonic nociception in fibromyalgia. Curr Pharm Des (in press)
68.
Staud R, Vierck CJ Jr, Cannon RC, Mauderli AP, Price DD (2001) Abnormal sensitization and temporal summation of second pain (wind-up) in patients with fibromyalgia syndrome. Pain 91:165–175CrossRefPubMed
69.
Li J, Simone DA, Larson AA (1999) Windup leads to characteristics of central sensitization. Pain 79:75–82CrossRefPubMed
70.
Schaible HG, Ebersberger A, von Banchet GS (2001) Mechanisms of pain in arthritis. Ann N Y Acad Sci 966:343–354CrossRef
71.
Staud R, Price DD, Robinson ME, Mauderli AP, Vierck CJ (2004) Maintenance of windup of second pain requires less frequent stimulation in fibromyalgia patients compared to normal controls. Pain 110:689–696CrossRefPubMed
72.
Vierck CJ Jr, Staud R, Price DD, Cannon RL, Mauderli AP, Martin AD (2001) The effect of maximal exercise on temporal summation of second pain (windup) in patients with fibromyalgia syndrome. J Pain 2:334–344CrossRefPubMed
73.
Staud R, Cannon RC, Mauderli AP, Robinson MD, Price DD, Vierck CJ Jr (2003) Temporal summation of pain from mechanical stimulationof muscle tissue of normal controls and subjects with fibromyalgia. Pain 102:87–95CrossRefPubMed
74.
Staud R, Robinson ME, Vierck CJ Jr, Cannon RL, Mauderli AP, Price DD (2003) Ratings of experimental pain and pain-related negative affect predict clinical pain in patients with fibromyalgia syndrome. Pain 105:215–222CrossRefPubMed
75.
Graven-Nielsen T, Aspegren Kendall S, Henriksson KG, Bengtsson M, Sorensen J, Johnson A, Gerdle B, Arendt-Nielsen L (2000) Ketamine reduces muscle pain, temporal summation, and referred pain in fibromyalgia patients. Pain 85:483–491CrossRefPubMed
76.
Price DD, Staud R, Robinson ME, Mauderli AP, Cannon R, Vierck CJ Jr (2002) Enhanced temporal summation of second pain and its central modulation in fibromyalgia patients. Pain 99:49–59CrossRefPubMed
77.
Staud R, Vierck CJ, Robinson ME, Price DD (2005) Effects of the N-methyl-d-aspartate receptor antagonist dextromethorphan on temporal summation of pain are similar in fibromyalgia patients and normal control subjects. J Pain 6:323–332CrossRefPubMed
78.
Sprott H, Bradley LA, Oh SJ, Wintersberger W, Alarcon GS, Mussell HG, Tseng A, Gay RE, Gay S (1998) Immunohistochemical and molecular studies of serotonin, substance P, galanin, pituitary adenylyl cyclase-activating polypeptide, and secretoneurin in fibromyalgic muscle tissue. Arthritis Rheum 41:1689–1694CrossRefPubMed
79.
Sprott H, Salemi S, Gay RE, Bradley LA, Alarcon GS, Oh SJ, Michel BA, Gay S (2004) Increased DNA fragmentation and ultrastructural changes in fibromyalgic muscle fibres. Ann Rheum Dis 63:245–251CrossRefPubMed
80.
Delibas N, Ozcankaya R, Altuntas I (2002) Clinical importance of erythrocyte malondialdehyde levels as a marker of cognitive deterioration in patients with dementia of Alzheimer type: a repeated study in 5-year interval. Clin Biochem 32:137–141CrossRef
81.
Bilici M, Efe H, Koroglu MA, Uydu HA, Bekaroglu M, Deger O (2001) Antioxidative enzyme activities and lipid peroxidation in major depression: alterations by antidepressant treatments. J Affect Disord 64:43–51CrossRefPubMed
82.
Akyol O, Isci N, Temel I, Ozgocmen S, Uz E, Murat M, Buyukberber S (2001) The relationships between plasma and erythrocyte antioxidant enzymes and lipid peroxidation in patients with rheumatoid arthritis. Joint Bone Spine 68:311–317CrossRef
83.
Ozgocmen S, Sogut S, Ardicoglu O, Fadillioglu E, Pekkutucu I, Akyol O (2004) Serum nitric oxide, catalase, superoxide dismutase, and malondialdehyde status in patients with ankylosing spondylitis. Rheumatol Int 24:80–83CrossRefPubMed
84.
Keenoy BM, Moorkens G, Vertommen J, Leeuw ID (2001) Antioxidant status and lipoprotein in chronic fatigue syndrome. Life Sci 68:2037–2049CrossRefPubMed
85.
Vecchiet J, Capillone F, Falasca K, Mezzetti A, Pizzigallo E, Bucciarelli T, De Laurentis S, Affaitati G, De Cesare D, Giamberardino MA (2004) Relationship between musculoskeletal symptoms and blood markers of oxidative stress in patients with chronic fatigue syndrome. Neurosci Lett 335:151–154CrossRef
86.
Kretnisky TA, Spector T, Hall WW (1986) Xantine oxidase from human liver: purification and characterisation. Arch Biochem Biophys 247:108–119CrossRefPubMed
87.
Esterbauer H, Schaur RJ, Zollner H (1991) Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 11:81–128CrossRefPubMed
88.
Sogut S, Zoroglu S, Ozyurt H, Yilmaz HR, Ozugurlu F, Sivasli E, Yetkin O, Yanik M, Tutkun H, Savas HA, Tarakcioglu M, Akyol O (2003) Changes in nitric oxide levels and antioxidant enzyme activities may have a role in the pathophysiological mechanisms involved in autism. Clin Chim Acta 331:111–117CrossRefPubMed
89.
Kigwell BA (2000) Nitric oxide-mediated metabolic regulation during exercise: effect of training in health and cardiovascular disease. FASEB J 14:1685–1696CrossRefPubMed
90.
Akyol O, Zoroglu SS, Armutcu F, Sahin S, Gurel A (2004) Nitric oxide as a physiopathological factor in neuropsychiatric disorders. In vivo 18:377–390PubMed
91.
92.
Granner DK (1996) Hormone action. In: Murray RK, Granner DK, Mayes PA, Rodwell VW (eds) Harper’s Biochemistry. Appleton & Lange Publications, Stamford, pp 509–521
93.
Imaizumi S, Kondo T, Deli MA, Gobbel G, Joo F, Epstein CJ, Yoshimoto T, Chan PH (1996) The influence of oxygen free radicals on the permeability of the monolayer of cultured brain endothelial cells. Neurochem Int 29:205–211CrossRefPubMed
94.
Thiel VE, Audus KL (2001) Nitric oxide and blood-brain barrier integrity. Antioxid Redox Signal 3:273–278CrossRefPubMed
95.
Clancy RM, Amin AR, Abramson SB (1998) The role of nitric oxide in inflammation and immunity. Arthritis Rheum 41:1141–1151CrossRefPubMed
96.
Stichtenoth DO, Frolich JC (1998) Nitric oxide and inflammatory joint diseases. Br J Rheumatol 37:246–257CrossRefPubMed
97.
98.
Lafon-Cazal M, Culcassi M, Gaven F, Pietri S, Bockaert J (1993) Nitric oxide, superoxide and peroxynitrite: putative mediators of NMDA-induced cell death in cerebellar cells. Neuropharmacology 32:1259–1266CrossRefPubMed
99.
100.
Callsen-Cencic P, Hoheisel U, Kaske A, Mense S, Tenschert S (1999) The controversy about spinal neuronal nitric oxide synthase: under which conditions is it up or downregulated? Cell Tissue Res 295:183–194CrossRefPubMed
101.
Li P, Tong C, Eisenach JC, Figueora JP (1994) NMDA causes release of nitric oxide from rat spinal cord in vitro. Brain Res 637:287–291CrossRefPubMed
102.
Mense S, Hohesiel U (1999) New developments in the understanding of the pathophysiology of muscle pain. J Musculoskelet Pain 7:13–24CrossRef
103.
Hoheisel U, Unger T, Mense S (2000) A block of spinal nitric oxide synthesis leads to increased background activity predominantly in nociceptive dorsal horn neurons in the rat. Pain 88:249–257CrossRefPubMed
104.
Eisinger J, Gandolfo C, Zakarian H, Ayavou T (1997) Reactive oxygen species, antioxidant status and fibromyalgia. J Musculoskelet Pain 5:5–15CrossRef
105.
Eisinger J, Plantamura A, Marie PA, Ayavou T (1994) Selenium and magnesium status in fibromyalgia. Magnes Res 7:285–288PubMed
106.
Romano TJ, Stiller JW (1994) Magnesium deficiency in fibromyalgia syndrome. J Nutr Med 4:165–167
107.
Bagis S, Tamer L, Sahin G, Bilgin R, Guler H, Ercan B, Erdogan C (2005) Free radicals and antioxidants in primary fibromyalgia: an oxidative stress disorder? Rheumatol Int 25:188–190CrossRefPubMed
108.
Ozgocmen S, Ozyurt H, Sogut S, Akyol O, Ardicoglu O, Yidizhan H (2005) Antioxidant status, lipid peroxidation and nitric oxide in fibromyalgia: etiologic and therapeutic concerns. Rheumatol Int (in press)
109.
Bradley LA, Weigent DA, Sotolongo A, Alarcon GS, Arnold RE, Cianfrini LR et al (2000) Blood serum levels of nitric oxide are elevated in women with fibromyalgia: possible contributions to central and peripheral sensitization. Arthritis Rheum 43:S173
110.
Sackner MA, Gummels EM, Adams JA (2004) Say NO to fibromyalgia and chronic fatigue syndrome: an alternative and complementary therapy to aerobic exercise. Med Hypotheses 63:118–123CrossRefPubMed
111.
Olsen NJ, Park JH (1998) Skeletal muscle abnormalities in patients with fibromyalgia. Proc Natl Acad Med USA 315:351–358
112.
113.
Lindh MH, Johansson LG, Hedberg M, Henning GB, Grimby G (1995) Muscle fiber characteristics, capillaries and enzymes in patients with fibromyalgia and controls. Scand J Rheumatol 24:34–37PubMed
114.
Bengtsson A, Henriksson KG (1989) The muscle in fibromyalgia: a review of Swedish studies. J Rheumatol 16:144–149
115.
Lindman R, Hagberg M, Bengtsson A, Henricksson KG, Thornell LE (1995) Capillary structure and mitochondrial volume density in the trapezius muscle of chronic trapezius myalgia, fibromyalgia, and healthy subjects. J Musculoskelet Pain 3:5–22CrossRef
116.
Lund N, Bengtsson A, Thorborg P (1986) Muscle oxygen tissue pressure in primary fibromyalgia. Scand J Rheumatol 15:165–173PubMed
117.
Elert JE, Rantapaa–Dahlqvist SB, Henriksson-Larsen K, Lorentzon R, Gerdle BU (1992) Muscle performance, electromyography and fiber type composition in fibromyalgia and work-related myalgia. Scand J Rheumatol 21:28–34PubMed
118.
Bennett RM, Clark SR, Goldberg L, Nelson D, Bonafede RP, Porter J, Specht D (1989) Aerobic fitness in patients with fibrositis. A controlled study of respiratory gas exchange and 133xenon clearance from exercising muscle. Arthritis Rheum 32:454–460PubMed
119.
Holloszy JO, Coyle EF (1984) Adaptations of skeletal muscle to endurance exercise and their metabolic consequences. J Appl Physiol 56:831–838PubMed
120.
Jeschonneck M, Graohmann G, Hein G, Sprott H (2000) Abnormal microcirculation and temperature in skin above tender points in patients with fibromyalgia. Rheumatology 39:917–921CrossRefPubMed
121.
Gronemann ST, Ribel–Madsen S, Bartels EM, Danneskiold-Samsoe B, Bliddal H (2004) Collagen and muscle pathology in fibromyalgia patients. Rheumatology 43:27–31CrossRefPubMed
122.
Frodin T, Bengtsson A, Skogh M (1988) Nail fold capillaroscopy findings in patients with primary fibromyalgia. Clin Rheumatol 7:384–388CrossRefPubMed
123.
Violi F, Marino R, Milite MT, Loffredo L (1999) Nitric oxide and its role in lipid peroxidation. Diabetes Metab Res Rev 15:283–288CrossRefPubMed
124.
Lund E, Kendall SA, Janerot-Sjoberg B, Bengtsson A (2003) Muscle metabolism in fibromyalgia studied by P-31 magnetic resonance spectroscopy during aerobic and anaerobic exercise. Scand J Rheumatol 32:138–145CrossRefPubMed
125.
Sprott H, Rzanny R, Reichenbach JR, Kaiser WA, Hein G, Stein G (2000) 31 P magnetic resonance spectroscopy in fibromyalgia muscle. Rheumatology 39:1121–1125CrossRefPubMed
126.
Jubrias SA, Bennett RM, Klug GA (1994) Increased incidence of a resonance in the phosphodiester region of 31P nuclear magnetic resonance spectra in the skeletal muscle of fibromyalgia patients. Arthritis Rheum 37:801–807PubMed
127.
Park JH, Phothimat P, Oates CT, Hernanz-Schulman M, Olsen NJ (1998) Use of P-31 magnetic resonance spectroscopy to detect metabolic abnormalities in muscles of patients with fibromyalgia. Arthritis Rheum 41:406–413CrossRefPubMed
128.
Larsson B, Bjork J, Kadi F, Lindman R, Gerdle B (2004) Blood supply and oxidative metabolism in muscle biopsies of female cleaners with and without myalgia. Clin J Pain 20:440–446PubMed
129.
Wysenbeek AJ, Shapira Y (1991) Primary fibromyalgia and the chronic fatigue syndrome. Rheumatol Int 10:227–229CrossRefPubMed
130.
Hudson JI, Goldenberg DL, Pope HG, Keck PE, Schleisenger L (1992) Comorbidity of fibromyalgia with medical and psychiatric disorders. Am J Med 92:363–367CrossRefPubMed
131.
White KP, Speechley M, Harth M, Ostbye T (2000) Co-existence of chronic fatigue syndrome with fibromyalgia syndrome in the general population. Scand J Rheumatol 29:44–51CrossRefPubMed
132.
Fulle S, Mecocci P, Fano G, Vecchiet I, Vecchini A, Racciotti D, Cherubini A, Pizzigallo E, Vecchiet L, Senin U, Beal MF (2000) Specific oxidative alterations in vastus lateralis muscle of patients with the diagnosis of chronic fatigue syndrome. Free Radic Biol Med 29:1252–1259CrossRefPubMed
133.
Keenoy MB, Moorkens G, Vertommen J et al (2000) Magnesium status and parameters of the oxidant-antioxidant balance in patients with chronic fatigue syndrome: effect of supplementation with magnesium. J Am Coll Nutr 19:374–382PubMed
134.
Grant JE, Veldee MS, Buchwald D (1996) Analysis of dietary intake and selected nutrient concentrations in patients with chronic fatigue syndrome. J Am Diet Assoc 96:383–386CrossRefPubMed
135.
Logan AC, Wong C (2001) Chronic fatigue syndrome: oxidative stress and dietary modifications. Altern Med Rev 6:450–459PubMed
136.
Richards RS, Roberts TK, McGregor NR, Dunstan RH, Butt HL (2000) Blood parameters indicative of oxidative stress are associated with symptoms expression in chronic fatigue syndrome. Redox Rep 5:35–41CrossRefPubMed
137.
Pall ML, Satterlee JD (2001) Elevated nitric oxide/peroxynitrite mechanism for the common etiology of multiple chemical sensitivity, chronic fatigue syndrome, and posttraumatic stress disorder. Ann N Y Acad Sci 933:323–329PubMedCrossRef
138.
Pall ML (2002) Levels of nitric oxide synthase product citrulline are elevated in sera of chronic fatigue syndrome patients. J Chronic Fatigue Syndr 10:37–41CrossRef
139.
Nijs J, van de Velde B, De Meirleir K (2005) Pain in patients with chronic fatigue syndrome: Does nitric oxide trigger central sensitization? Med Hypotheses 64:558–562CrossRefPubMed
140.
Evans PH (1993) Free radicals in brain metabolism and pathology. Br Med Bull 49:577–587PubMed
141.
Iraz M, Erdogan H, Ozyurt B, Ozugurlu F, Ozgocmen S, Fadillioglu E (2005) Omega-3 essential fatty acid supplementation and erythrocyte oxidant/antioxidant status in rats. Ann Clin Lab Sci 35:169–173PubMed
142.
Merchant RE, Carmack CA, Wise CM (2000) Nutritional supplementation with Chlorella pyrenoidosa for patients with fibromyalgia syndrome: a pilot study. Phytother Res 14:167–173CrossRefPubMed
143.
Ozgocmen S, Catal SA, Ardicoglu O, Kamanli A (2000) Effect of omega-3 fatty acids in the management of fibromyalgia syndrome. Int J Clin Pharmacol Ther 38:362–363PubMed
144.
Hostmark AT, Lystad E, Vellar OD, Hovi K, Berg JE (1993) Reduced plasma fibrinogen, serum peroxides, lipids, and apolipoproteins after a 3-week vegetarian diet. Plant Foods Hum Nutr 43:55–61CrossRefPubMed
Metadata
Title
Current concepts in the pathophysiology of fibromyalgia: the potential role of oxidative stress and nitric oxide
Authors
Salih Ozgocmen
Huseyin Ozyurt
Sadik Sogut
Omer Akyol
Publication date
01-05-2006
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 7/2006
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-005-0078-z

Other articles of this Issue 7/2006

Rheumatology International 7/2006 Go to the issue

Original Article

Antioxidant status, lipid peroxidation and nitric oxide in fibromyalgia: etiologic and therapeutic concerns

Case Report

Henoch-Schönlein purpura: a case with atypical presentation

Case Report

Coexistence of osteopoikilosis with reactive arthritis: a case report

Original Article

The phenotype–genotype correlations of FMF patients: a single center study

Case Report

Acute monocular visual loss in carcinomatous hypertrophic pachymeningitis mimicking giant cell arteritis

Original Article

Nailfold videocapillaroscopy in patients with systemic lupus erythematosus
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits